Ixazomib: a novel drug for multiple myeloma.

Zanwar S et al. Expert Rev Hematol. 2018 Sep 1. doi: 10.1080/17474086.2018.1518129. [Epub ahead of print]

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

San-Miguel JF et al. Haematologica. 2018 Sep. doi: 10.3324/haematol.2017.185991. [Epub 2018 Jun 28]

Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.

Cho H et al. Invest New Drugs. 2018 Oct. doi: 10.1007/s10637-018-0582-0. [Epub 2018 Mar 9]